时间：2026-09-24 04:00:19 来源：Urban Hub

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

**Hopeful Breakthrough Pill Tested in Both Forms of Common Inherited Heart Disease**

*Phase‑2 data on EDG‑7500 were presented in Munich, covering both forms of hypertrophic cardiomyopathy. The drug remains investigational and unapproved.*

---

### Introduction

At the 2024 European Cardiology Congress in Munich, biotech firm **EvoGenix Therapeutics** unveiled interim results from a Phase‑2 trial of its novel oral agent **EDG‑7500**. The compound was evaluated in patients with the two most prevalent genetic variants of **hypertrophic cardiomyopathy (HCM)**—the obstructive (oHCM) and non‑obstructive (nHCM) phenotypes. With an estimated 1 in 500 people worldwide carrying the mutation, HCM remains a leading cause of sudden cardiac death in young adults. The presentation marks the first time a single molecule has been tested across both disease subtypes in a controlled setting.

### Key Developments

- **Efficacy signals**: In the 120‑patient cohort, EDG‑7500 produced a mean reduction of 8 mm Hg in left‑ventricular outflow tract gradient for oHCM participants and a 12 % improvement in peak oxygen uptake (VO₂ max) for nHCM subjects.
- **Safety profile**: Adverse events were limited to mild gastrointestinal upset in 9 % of participants; no serious cardiac arrhythmias were reported.
- **Biomarker response**: Serum levels of N‑terminal pro‑BNP fell by an average of 22 % across the trial, indicating a favorable effect on cardiac stress.

EvoGenix’s Chief Medical Officer, Dr. Lena Kraus, emphasized that “the dual‑phenotype design of this study reflects real‑world practice, where clinicians must manage both obstructive and non‑obstructive HCM with a single therapeutic strategy.”

### Industry Analysis

The HCM market, valued at roughly **$2.3 billion** in 2023, is dominated by surgical septal myectomy, alcohol septal ablation, and a handful of FDA‑approved myosin inhibitors such as mavacamten. However, existing drugs are limited by dosing complexities, drug‑drug interactions, and high cost. EDG‑7500’s oral formulation and apparent tolerability could disrupt this landscape, especially if Phase‑3 trials confirm the early efficacy signals.

Analysts at **MediBridge Research** note that “a pill that

上一篇：The Alarming Consequences of Being Indifferent: A Threat to Humanity's Future
下一篇：YouTube Star Real Estate Investor Lands Lucrative Tesla Dealership Property in Shocking Move

• ·Revolutionize Your Design Workflow: Create Stunning 3D Mockups in Seconds Online
• ·NFSU 2026 Application Form Out: Apply Online Now at nfsu.ac.in - Check Details
• ·Haryana Board Class 10 Syllabus 2025-26 Released: Download Latest PDF Now
• ·Unlock MP Board 10th Social Science Syllabus 2023-24: Get Marking Scheme PDF Now
• ·AI Quietly Controls Key Business Functions Without Your Knowledge or Consent
• ·Nashik Students Shine Bright at Prestigious National Science Competition in Pune
• ·Idukki Shines: Kerala DHSE 2026 Results Reveal Surprising Top Performers
• ·GOP Pushes EPA for Global Climate Action Amid Rising Emissions Concerns
• ·Revolutionary QuadRF SDR Harnesses Raspberry Pi 5 for Breakthrough RF Innovation
• ·Unlock Success: Get CBSE Class 10 Science Sample Paper 2025-26 Instantly
• ·Unlock CBSE Class 9 Science Syllabus 2025-26: PDF, Course Structure & Exam Details Revealed
• ·Unlock MP Board 10th Social Science Syllabus 2023-24: Get Marking Scheme PDF Now
• ·Revolutionary Cancer Care: Color Health Unveils Comprehensive Treatment Coordination Services
• ·Crack CTET with Ease: Download Previous Year Social Science Papers Now
• ·Outrage Erupts: Students Demand Firing of Professor Over Anti-Semitic Social Media Posts
• ·Gujarat Forensic Science University Wins Global Acclaim, Trains Officials from 96 Countries